Status:
COMPLETED
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborating Sponsors:
Rising Tide Foundation
Conditions:
Hematopoietic Stem Cell Transplantation
Delirium
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Purpose: To conduct a randomized controlled pilot study investigating the use of high dose intravenous (IV) thiamine to prevent delirium and mitigate the long-term effects of delirium, including healt...
Detailed Description
Delirium is a common and potentially preventable neuropsychiatric complication in cancer patients receiving hematopoietic stem cell transplantation (HSCT) that has profound consequences. Among cancer ...
Eligibility Criteria
Inclusion
- Admission to the UNC Hospital Bone Marrow Transplant Unit for allogeneic stem cell transplant
- At least 18 years of age
- Able to speak English
- Able to provide informed consent
Exclusion
- A history of adverse reaction to IV thiamine
- Pregnancy, confirmed by a negative pregnancy test within 30 days of study enrollment
Key Trial Info
Start Date :
October 16 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 10 2020
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT03263442
Start Date
October 16 2017
End Date
August 10 2020
Last Update
October 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27514